Luis Rodrigues, CEO and Co-Founder of Kinetikos Health

In their next P4SY Accelerator Programme Founder interview, the team has been talking with Luis Rodrigues, CEO and Co-Founder of Kinetikos Health.


CEO: Luis Rodrigues
Programme: P4SY
Sector: Precision Medicine
Location: Sheffield 
Website: Kinetikos Health 

Thank you for joining us. So –

What is Kinetikos?

Kinetikos is a software solution which supports both patients and clinicians in Parkinson’s management. It includes a patient app – mKinetikos – which monitors mobility, allows completion of tests and patient reported outcome measures (PROMs), and facilitates medication changes and communication with the clinical team. Clinicians can access this information and remotely manage their patients via the Kinetikos web dashboard. Here they can see real-time monitoring data, modify prescriptions, communicate with patients and send out tests for patients to complete.

Current technologies available that demonstrate motor problems or responses to treatment to enable optimal medication usage provide monitoring for a defined period of time (approx 7 days) and are wearable dependant. Our technology provides real-time, continuum monitoring and it’s not wearable dependent.

Who have you created Kinetikos for?

The ability to monitor people living with Parkinson’s on a daily basis through mKinetikos could help to act as an early warning system that they are experiencing problems and require medication or treatment adjustment to reduce deterioration and prevent hospital admissions.

Patients are typically seen annually (for complex patients this may be a 6-month review). There is however a national requirement to reduce outpatient follow-up appointments as Trusts are struggling with workforce capacity. The main benefit is enabling patient-monitoring at home rather than hospital outpatient appointments.

From a patient perspective, it improves their quality of life and allows self-management. From a clinician’s perspective, the ability to have an early warning system and advanced analytics on patients improves staff capacity.

A recent health economic review conducted by SEHTA (South East Health Technologies Alliance) estimated that through a combination of reduction in non-elective admissions and delay in progression of the disease, the use of the Kinetikos platform could deliver 3 times the return on investment in the first year of deployment in care pathways.

What are the key successes you have achieved in your scale-up journey?

We’ve had many!

Our technology is validated as accurate as the current gold standard in movement analysis and mentioned in 25+ scientific publications.

mKinetikos app is ORCHA certified with a score of 83% and is now DTAC certified for adoption in the NHS. The Digital Technology Assessment Criteria for health and social care (DTAC) gives staff, patients and citizens confidence that the digital health tools they use meet NHS clinical safety, data protection, technical security, interoperability and usability and accessibility standards.

We’ve raised €1million across a Seed round with Pathena Investments and Adana Ventures, and successfully been awarded a number of important grants including Kinetikos4PD: an IDT grant from P2020 and the EU to develop our technology, the European Space Agency BA grant programme, and  H2020 ProCare4life 3 year grant as consortium leader for chronic diseases.

What connections / partnerships are you seeking to make for the next stage of your business growth?

We are seeking to make connections/partnerships with decision-makers that support the adoption of technology in the NHS as well as academia, patient groups, charities and clinical teams. We can bring budget savings to Trusts, CCGs and ICSs, increase efficiency in resource management to health providers and increase ways for people living with Parkinson’s to self-manage their condition, which ultimately benefits the health system. To have the right connections and ambassadors in all of these groups is of the utmost importance for us.

We are progressing the negotiations of our Series-A financing round that we expect to conclude by year end to properly fuel our market access over the next three years.

And finally, can you tell us about your experience of participating in the P4SY Accelerator Programme?

P4SY accelerator has been instrumental in helping us establish our company in South Yorkshire. Pippa and Tamara have supported us by finding a location that suits our immediate needs which allows us to grow organically within the region.

They have introduced us to key stakeholders with whom we are already establishing partnerships in key projects that will help us grow our business in the region and scale it to the rest of the country. On top of this, the advice and guidance that has been provided have enabled us to secure some essential funding to support our internationalisation.

To find out more visit the Kinetikos Health website, view content here, or contact